203 related articles for article (PubMed ID: 23377194)
1. The effects of drospirenone-ethinyl estradiol and drospirenone-ethinyl estradiol + metformin on ovarian ultrasonographic markers, body fat mass index, leptin, and ghrelin.
Cakiroglu Y; Vural B; Isgoren S
Arch Gynecol Obstet; 2013 Jul; 288(1):213-20. PubMed ID: 23377194
[TBL] [Abstract][Full Text] [Related]
2. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
3. Effects of drospirenone-ethinylestradiol and/or metformin on CD4(+)CD28(null) T lymphocytes frequency in women with hyperinsulinemia having polycystic ovary syndrome: a randomized clinical trial.
Moro F; Morciano A; Tropea A; Sagnella F; Palla C; Scarinci E; Ciardulli A; Martinez D; Familiari A; Liuzzo G; Tritarelli A; Cosentino N; Niccoli G; Crea F; Lanzone A; Apa R
Reprod Sci; 2013 Dec; 20(12):1508-17. PubMed ID: 23690338
[TBL] [Abstract][Full Text] [Related]
4. The effects of oral contraceptives including low-dose estrogen and drospirenone on the concentration of leptin and ghrelin in polycystic ovary syndrome.
Sağsöz N; Orbak Z; Noyan V; Yücel A; Uçar B; Yildiz L
Fertil Steril; 2009 Aug; 92(2):660-6. PubMed ID: 18973889
[TBL] [Abstract][Full Text] [Related]
5. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination.
Aydin K; Cinar N; Aksoy DY; Bozdag G; Yildiz BO
Contraception; 2013 Mar; 87(3):358-62. PubMed ID: 22898361
[TBL] [Abstract][Full Text] [Related]
6. Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome.
Cinar N; Harmanci A; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Mar; 78(3):379-84. PubMed ID: 22509734
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
8. The effect of drospirenone (3 mg) with ethinyl estradiol (30 mcg) containing pills on ovarian blood flows in women with polycystic ovary syndrome: a case controlled study.
Okyay E; Gode F; Acet F; Bodur T; Cagliyan E; Sahan C; Posaci C; Gulekli B
Eur J Obstet Gynecol Reprod Biol; 2014 Sep; 180():93-9. PubMed ID: 25063905
[TBL] [Abstract][Full Text] [Related]
9. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
10. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2005 Jan; 90(1):39-43. PubMed ID: 15483105
[TBL] [Abstract][Full Text] [Related]
11. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
Ibáñez L; Valls C; Cabré S; De Zegher F
J Clin Endocrinol Metab; 2004 Sep; 89(9):4716-20. PubMed ID: 15356085
[TBL] [Abstract][Full Text] [Related]
12. L-arginine plus drospirenone-ethinyl estradiol in the treatment of patients with PCOS: a prospective, placebo controlled, randomised, pilot study.
Battaglia C; Mancini F; Battaglia B; Facchinetti F; Artini PG; Venturoli S
Gynecol Endocrinol; 2010 Dec; 26(12):861-8. PubMed ID: 20642382
[TBL] [Abstract][Full Text] [Related]
13. Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel on clinical and biochemical parameters in patients with polycystic ovary syndrome.
Kriplani A; Periyasamy AJ; Agarwal N; Kulshrestha V; Kumar A; Ammini AC
Contraception; 2010 Aug; 82(2):139-46. PubMed ID: 20654754
[TBL] [Abstract][Full Text] [Related]
14. The effects of treatment with drospirenone/ethinyl oestradiol alone or in combination with metformin on elastic properties of aorta in women with polycystic ovary syndrome.
Kaya MG; Calapkorur B; Karaca Z; Yildirim S; Celik A; Akpek M; Unluhizarci K; Kelestimur F
Clin Endocrinol (Oxf); 2012 Dec; 77(6):885-92. PubMed ID: 22563947
[TBL] [Abstract][Full Text] [Related]
15. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Harmanci A; Cinar N; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
[TBL] [Abstract][Full Text] [Related]
16. Drospirenone/ethinyl estradiol versus rosiglitazone treatment in overweight adolescents with polycystic ovary syndrome: comparison of metabolic, hormonal, and cardiovascular risk factors.
Tfayli H; Ulnach JW; Lee S; Sutton-Tyrrell K; Arslanian S
J Clin Endocrinol Metab; 2011 May; 96(5):1311-9. PubMed ID: 21325466
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Apelin and Insulin Resistance in Patients with PCOS and Therapeutic Effect of Drospirenone-Ethinylestradiol Plus Metformin.
Sun X; Wu X; Zhou Y; Yu X; Zhang W
Med Sci Monit; 2015 Aug; 21():2547-52. PubMed ID: 26314870
[TBL] [Abstract][Full Text] [Related]
18. The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers.
Christakou C; Kollias A; Piperi C; Katsikis I; Panidis D; Diamanti-Kandarakis E
Hormones (Athens); 2014; 13(4):488-97. PubMed ID: 25555182
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovary syndrome and cardiovascular risk in young patients treated with drospirenone-ethinylestradiol or contraceptive vaginal ring. A prospective, randomized, pilot study.
Battaglia C; Mancini F; Fabbri R; Persico N; Busacchi P; Facchinetti F; Venturoli S
Fertil Steril; 2010 Sep; 94(4):1417-1425. PubMed ID: 19591981
[TBL] [Abstract][Full Text] [Related]
20. Basal and meal-stimulated ghrelin, PYY, CCK levels and satiety in lean women with polycystic ovary syndrome: effect of low-dose oral contraceptive.
Arusoglu G; Koksal G; Cinar N; Tapan S; Aksoy DY; Yildiz BO
J Clin Endocrinol Metab; 2013 Nov; 98(11):4475-82. PubMed ID: 24001751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
